The Food and Drug Administration announced on Thursday that popular obesity and Type 2 diabetes medications do not have a clear risk of patients developing depression and suicidal thoughts.

The agency published its initial findings after a monthslong review of information from the FDA Adverse Event Reporting System on the entire drug class of GLP1 RAs, which include Ozempic, Wegovy, Mounjaro, and Zepbound.

Recommended Stories

FDA approves first over-the-counter hormonal birth control pill

FDA advisors recommend Eli Lilly Alzheimer’s drug that slows disease

Berberine: Experts warn ‘nature’s Ozempic’ not worth its weight